跳转至内容
Merck
CN

SML1175

罗咪酯肽

≥98% (HPLC), powder, histone deacetylase inhibitor

别名:

FK228, FR901228, L-缬氨酸, N-((3S,4E)-3-羟基-7-巯基-1-氧代-4-庚基)-D-戊基-D-半胱氨酸-(2Z)-2-氨基-2-丁烯氧基-, (4-1)-内酯,环状(1-2)-二硫化物, 环[(2Z)-2-氨基-2-丁烯酰基-L-戊基-(3S,4E)-3-羟基-7-巯基-4-庚烯酰基-D-戊基-D-半胱氨酰]环状(35)-二硫化物, 缩酚酸肽

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C24H36N4O6S2
化学文摘社编号:
分子量:
540.70
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

罗咪酯肽, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 25 mg/mL, clear

storage temp.

−20°C

SMILES string

O=C(N/C(C(N[C@@H](C(C)C)C(O[C@@]1([H])CC2=O)=O)=O)=C\C)[C@@H](CSSCC/C=C/1)NC([C@H](N2)C(C)C)=O

InChI

1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1

InChI key

OHRURASPPZQGQM-GCCNXGTGSA-N

Biochem/physiol Actions

罗米地辛可促进细胞凋亡,同时阻碍神经胶质瘤模型中肿瘤的生长。
罗米地辛是HDAC1和HDAC2的一种非常有效的天然前药抑制剂,可被谷胱甘肽转化为活性形式。罗米地辛对HDAC1和HDAC2的IC50 值分别为36 nM和47 nM。它可杀死过表达Bcl-2和Bcl-XL的淋巴瘤细胞系,并已被批准用于治疗皮肤T细胞淋巴瘤(CTCL)和外周T细胞淋巴瘤,以及多种其他癌症。
罗米地辛是HDAC1和HDAC2的非常有效的天然前药抑制剂;抗肿瘤药。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Anna Otte et al.
International journal of oncology, 49(6), 2453-2463 (2016-10-18)
Chemotherapeutic drug testing of SCCOHT-1 and BIN-67 tumor cells revealed synergistic growth-inhibition of >95% in vitro with a combination of foretinib and FK228. Application of this drug combination in vivo in NODscid mice-induced SCCOHT-1GFP tumors was associated with ~6-fold reduction in
Minsun Jung et al.
The oncologist, 24(8), e740-e748 (2019-01-31)
NUT carcinoma is a rare aggressive disease caused by BRD4/3-NUT fusion, and C-MYC upregulation plays a key role in the pathogenesis. Here, we report on the clinicopathological characteristics of Korean patients with NUT carcinoma and the in vitro efficacy of
YiHan Wu et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 84, 462-469 (2016-09-30)
Temozolomide is a novel cytotoxic agent currently used as first-line chemotherapy for glioblastoma multiforme (GBM). Romidepsin (FK228), a histone deacetylase inhibitor, is a promising new class of antineoplastic agent with the capacity to induce growth arrest and/or apoptosis of cancer
Florencia Cayrol et al.
Nature communications, 8, 14290-14290 (2017-01-31)
Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poor response to chemotherapy and dismal survival. Identification of effective strategies to target PTCL biology represents an urgent need. Here we report that PTCL are sensitive to transcription-targeting drugs, and, in particular
Cai-Ping Chen et al.
Acta pharmaceutica Sinica. B, 9(5), 937-951 (2019-10-28)
Artemisinin and its derivatives (ARTs) were reported to display heme-dependent antitumor activity. On the other hand, histone deacetylase inhibitors (HDACi) were known to be able to promote heme synthesis in erythroid cells. Nevertheless, the effect of HDACi on heme homeostasis

全球贸易项目编号

货号GTIN
SML1175-1MG04061826274460

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持